OpenAI Acquires Drug Tool to Speed Slow Drug Development Workflows
The deal adds Orchestra’s AI agents to Rosalind as OpenAI seeks to cut drug development timelines that often run 10 to 15 years.
7 Articles
7 Articles
Exclusive: OpenAI has acquired Orchestra Bio
OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development, the ChatGPT maker shared exclusively with Axios. Why it matters: Rival AI giants OpenAI and Anthropic are both pushing into science as they look to expand beyond their core competencies in coding and cybersecurity. State of play: OpenAI will integrate Orchestra's team and technology into Rosalind, its suite of AI models and t…
OpenAI Buys Orchestra Bio to Expand AI’s Role in Drug Development
OpenAI has acquired Orchestra Bio, a startup whose platform coordinates drug development, as the AI company expands its efforts to... The post OpenAI Buys Orchestra Bio to Expand AI’s Role in Drug Development appeared first on citybiz.
OpenAI acquired Orchestra Bio to integrate its pharmaceutical program coordination platform with Rosalind, its Life Sciences suite, in a bid to bring AI agents closer to the day-to-day work of scientific teams.
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
